JSPR · Company research
Jasper Therapeutics, Inc. Common Stock (JSPR): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Kidney study cohort enrollment ends at Jasper Therapeutics (JSPR), with interim data expected by year-end 2026. - Stock Titan | Kidney study cohort enrollment ends at Jasper Therapeutics (JSPR), with interim data expected by year-end 2026. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| A kidney disease study enrolled 18 people. Initial data are expected by year-end. - Stock Titan | A kidney disease study enrolled 18 people. Initial data are expected by year-end. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| Jasper Therapeutics, Inc. (JSPR) stock price, news, quote and history - Yahoo Finance UK | Jasper Therapeutics, Inc. (JSPR) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 7, 2026 | neutral | 0 | 0.6 |
| All outstanding warrants are eligible for Jasper Therapeutics (JSPR)'s cash purchase offer. - Stock Titan | All outstanding warrants are eligible for Jasper Therapeutics (JSPR)'s cash purchase offer. Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| Jasper Therapeutics (JSPR) Slides 5.52% to $0.56, Pressing Against Key Support Near $0.53 - Value Factor - dars.gov.et | Jasper Therapeutics (JSPR) Slides 5.52% to $0.56, Pressing Against Key Support Near $0.53 - Value Factor dars.gov.et | View source ↗ | dars.gov.et | Oct 7, 2026 | neutral | 0 | 0.6 |
| Jasper Therapeutics (JSPR) Slides 5.52% to $0.56, Pressing Against Key Support Near $0.53 - Sentiment Divergence - https://www.dars.gov.et/ | Jasper Therapeutics (JSPR) Slides 5.52% to $0.56, Pressing Against Key Support Near $0.53 - Sentiment Divergence https://www.dars.gov.et/ | View source ↗ | https://www.dars.gov.et/ | Oct 7, 2026 | neutral | 0 | 0.6 |
| Stockholders give Jasper Therapeutics (JSPR) until December 31, 2026 to decide on a reverse split. - Stock Titan | Stockholders give Jasper Therapeutics (JSPR) until December 31, 2026 to decide on a reverse split. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| A biotech company's New York talk will be webcast live - Stock Titan | A biotech company's New York talk will be webcast live Stock Titan | View source ↗ | Stock Titan | Sep 9, 2026 | neutral | 0 | 0.6 |
| Jasper Therapeutics (NASDAQ: JSPR) on clock after Nasdaq equity warning - Stock Titan | Jasper Therapeutics (NASDAQ: JSPR) on clock after Nasdaq equity warning Stock Titan | View source ↗ | Stock Titan | Aug 26, 2026 | neutral | 0 | 0.6 |
| Piper Sandler initiates Jasper Therapeutics stock at overweight - Investing.com | Piper Sandler initiates Jasper Therapeutics stock at overweight Investing.com | View source ↗ | Investing.com | Aug 12, 2026 | neutral | 0 | 0.6 |
| Jasper Therapeutics Announces Merger with Kira Pharmaceuticals - GlobeNewswire | Jasper Therapeutics Announces Merger with Kira Pharmaceuticals GlobeNewswire | View source ↗ | GlobeNewswire | Jul 16, 2026 | neutral | 0 | 0.6 |
| Jasper Therapeutics completes Kira acquisition, secures $132M financing to fund pipeline into H2 2028 - TradingView | Jasper Therapeutics completes Kira acquisition, secures $132M financing to fund pipeline into H2 2028 TradingView | View source ↗ | TradingView | Jul 16, 2026 | neutral | 0 | 0.6 |
| Jasper Therapeutics Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail | Jasper Therapeutics Receives Nasdaq Minimum Bid Price Notice The Globe and Mail | View source ↗ | The Globe and Mail | Jun 10, 2026 | neutral | 0 | 0.6 |
| Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now - Yahoo Finance | Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now Yahoo Finance | View source ↗ | Yahoo Finance | Jun 3, 2026 | neutral | 0 | 0.6 |
| Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire | Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire | View source ↗ | GlobeNewswire | May 14, 2026 | neutral | 0 | 0.6 |
| Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7 - Yahoo Finance | Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7 Yahoo Finance | View source ↗ | Yahoo Finance | Apr 7, 2026 | neutral | 0 | 0.6 |
| Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab - Yahoo Finance | Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab Yahoo Finance | View source ↗ | Yahoo Finance | Mar 29, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Mar 26, 2024 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.